Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Why invest in RGS?
Regeneus Ltd: THE INVESTMENT CASE
INVESTMENT OVERVIEW

Regeneus: Access latest PPT from Proactive's CEO Sessions

John Martin discussed regenerative medicine with investors.
Regeneus: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: RGS The Big Picture
John Martin, chief executive officer, Regeneus

Regeneus (ASX:RGS) chief executive officer, John Martin, joined Proactive's CEO Sessions in Sydney on Wednesday 14th June and Melbourne on Thursday 15th June.

The company provides exposure to the rapid growth global regenerative medicine market, utlising its world-calss stem cell and immuno-oncology technology platforms.

Its technology has been validated by positive pre-clinical and clinical data, and by a collaboration with a leading biopharma manufacturer in Japan.
 

ACCESS THE FULL PRESENTATION HERE

View full RGS profile View Profile

Regeneus Ltd Timeline

Related Articles

pills
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use